Latest

3 stories

Hide weekly roundups

Yesterday

Standard BioTools switches mass cytometry buyer to GMT Venture unit, ends Multiplex Bio deal

Standard BioTools terminated its Multiplex Bio sale and signed a new $5.5 million deal with Element Biosystems, a GMT Venture affiliate, after finding the offer superior.

SEC filing

Wednesday, August 5

Quarterly updateStandard Biotools Inc.

Standard BioTools reports Q2 2026 results, says Treeline merger on track to close by year-end

The company reiterated its merger with Treeline Biosciences is progressing toward a stockholder vote and expected close before year-end 2026, while withdrawing full-year revenue guidance.

SEC filing

Tuesday, July 28

M&AStandard Biotools Inc.

Standard BioTools agrees to sell Mass Cytometry unit, gets $30M Illumina payout

The deal with Multiplex Bio is pending stockholder approval and expected to close alongside the Treeline merger by year-end 2026.

SEC filing